A stepwise responsive Au-SS-PEG/Sor/ATPaptamer/LHRH-MPGΔNLS drug delivery vector system for overcoming drug resistance in immunotherapy of hepatocellular carcinoma.

IF 4.6 3区 材料科学 Q2 CHEMISTRY, MULTIDISCIPLINARY
Mengting Tong, Guangpeng Chen, Yong Dong, Yubin Pan, Yanan Xue, Da Li
{"title":"A stepwise responsive Au-SS-PEG/Sor/ATP<sub>aptamer</sub>/LHRH-MPG<sup>ΔNLS</sup> drug delivery vector system for overcoming drug resistance in immunotherapy of hepatocellular carcinoma.","authors":"Mengting Tong, Guangpeng Chen, Yong Dong, Yubin Pan, Yanan Xue, Da Li","doi":"10.1039/d5na00056d","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the progress made in novel immunotherapy for hepatocellular carcinoma (HCC), drug resistance remains a challenging problem. In this study, we developed a stepwise nanodrug delivery system, known as Au-SS-PEG/Sor/ATP<sub>aptamer</sub>/LHRH-MPG<sup>ΔNLS</sup>, to adapt to the high concentrations of glutathione (GSH) and adenine nucleoside triphosphate/adenosines (ATP/ADO) found in cancer cells and the tumor microenvironment (TME). This system utilizes novel Au nanoclusters conjugated with disulfide-linked PEG as vectors to transport sorafenib (Sor) and an ATP-binding nucleic acid aptamer (ATP<sub>apt</sub>). It can enter HCC cells through luteinizing hormone-releasing hormone (LHRH)-MPG<sup>ΔNLS</sup> (LM). Within the cells, the disulfide bonds of the nanoclusters are cleaved by the high levels of GSH, leading to the release of Sor/ATPapt. This release can be further triggered by ATP/ADO, resulting in a stepwise drug release mechanism. Furthermore, this nanodrug system has exhibited the ability to overcome αPD-1 resistance in HCC tumors. In summary, our novel drug delivery system demonstrates a dramatic anti-HCC effect and holds great potential for treating HCC patients.</p>","PeriodicalId":18806,"journal":{"name":"Nanoscale Advances","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12422059/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanoscale Advances","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1039/d5na00056d","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the progress made in novel immunotherapy for hepatocellular carcinoma (HCC), drug resistance remains a challenging problem. In this study, we developed a stepwise nanodrug delivery system, known as Au-SS-PEG/Sor/ATPaptamer/LHRH-MPGΔNLS, to adapt to the high concentrations of glutathione (GSH) and adenine nucleoside triphosphate/adenosines (ATP/ADO) found in cancer cells and the tumor microenvironment (TME). This system utilizes novel Au nanoclusters conjugated with disulfide-linked PEG as vectors to transport sorafenib (Sor) and an ATP-binding nucleic acid aptamer (ATPapt). It can enter HCC cells through luteinizing hormone-releasing hormone (LHRH)-MPGΔNLS (LM). Within the cells, the disulfide bonds of the nanoclusters are cleaved by the high levels of GSH, leading to the release of Sor/ATPapt. This release can be further triggered by ATP/ADO, resulting in a stepwise drug release mechanism. Furthermore, this nanodrug system has exhibited the ability to overcome αPD-1 resistance in HCC tumors. In summary, our novel drug delivery system demonstrates a dramatic anti-HCC effect and holds great potential for treating HCC patients.

逐步响应的Au-SS-PEG/Sor/ATPaptamer/LHRH-MPGΔNLS药物传递载体系统在肝癌免疫治疗中克服耐药性
尽管肝细胞癌(HCC)的新型免疫疗法取得了进展,但耐药仍然是一个具有挑战性的问题。在这项研究中,我们开发了一种被称为Au-SS-PEG/Sor/ATPaptamer/LHRH-MPGΔNLS的逐步纳米药物递送系统,以适应癌细胞和肿瘤微环境(TME)中高浓度的谷胱甘肽(GSH)和腺嘌呤核苷三磷酸/腺苷(ATP/ADO)。该系统利用新型的金纳米团簇与二硫化物连接的聚乙二醇偶联作为载体来运输索拉非尼(Sor)和atp结合的核酸适体(ATPapt)。它可以通过促黄体生成素释放激素(LHRH)-MPGΔNLS (LM)进入HCC细胞。在细胞内,纳米簇的二硫键被高水平的谷胱甘肽劈开,导致Sor/ATPapt的释放。ATP/ADO可进一步触发这种释放,从而形成逐步的药物释放机制。此外,该纳米药物系统已显示出克服HCC肿瘤αPD-1耐药的能力。综上所述,我们的新型给药系统具有显著的抗HCC作用,在治疗HCC患者方面具有很大的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nanoscale Advances
Nanoscale Advances Multiple-
CiteScore
8.00
自引率
2.10%
发文量
461
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信